Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab
Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9b2b493dad8b492d8f6537d9d4349205 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9b2b493dad8b492d8f6537d9d4349205 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9b2b493dad8b492d8f6537d9d43492052021-12-02T02:56:42ZChemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab1177-5483https://doaj.org/article/9b2b493dad8b492d8f6537d9d43492052014-08-01T00:00:00Zhttp://www.dovepress.com/chemical-injury-treated-with-autologous-limbal-epithelial-stem-cell-tr-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena, Italy Background: Limbal stem cell (LSC) deficiency leads to corneal opacity due to a conjunctivalization of the corneal surface. LSC transplantation, which can be followed by corneal keratoplasty, is an effective procedure to restore corneal transparency; however, a common cause of failure of this procedure is neovascularization (NV).Methods: A 59-year-old man with a 21-year history of a corneal chemical burn caused by phosphoric acid in his left eye was examined. He presented with unilateral total LSC deficiency with severe conjunctivalization and a corrected distance visual acuity that was limited to hand motion.Results: We reported the short-term in vivo efficacy of subconjunctival bevacizumab for progressive corneal NV in a patient with LSC deficiency that underwent LSC transplantation. Four months after autologous LSC transplantation and 1 month after the second subconjunctival bevacizumab injection, the patient’s corrected distance visual acuity was 1/10.Conclusion: Subconjunctival injection of bevacizumab can reduce the corneal NV, reducing conjunctival inflammation and supporting restoration of a stable ocular surface that is able to counteract graft failure, with no toxicity for the transplanted LSC. Keywords: stem cells, bevacizumab, limbal stem cell deficiency, transplantationCavallini GMPellegrini GVolante VDucange PDe Maria MTorlai GBenatti CForlini MDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2014, Iss default, Pp 1671-1673 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Ophthalmology RE1-994 |
| spellingShingle |
Ophthalmology RE1-994 Cavallini GM Pellegrini G Volante V Ducange P De Maria M Torlai G Benatti C Forlini M Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| description |
Gian Maria Cavallini,1 Graziella Pellegrini,2 Veronica Volante,1 Pietro Ducange,1 Michele De Maria,1 Giulio Torlai,1 Caterina Benatti,1 Matteo Forlini1 1Institute of Ophthalmology, 2Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena e Reggio Emilia, Modena, Italy Background: Limbal stem cell (LSC) deficiency leads to corneal opacity due to a conjunctivalization of the corneal surface. LSC transplantation, which can be followed by corneal keratoplasty, is an effective procedure to restore corneal transparency; however, a common cause of failure of this procedure is neovascularization (NV).Methods: A 59-year-old man with a 21-year history of a corneal chemical burn caused by phosphoric acid in his left eye was examined. He presented with unilateral total LSC deficiency with severe conjunctivalization and a corrected distance visual acuity that was limited to hand motion.Results: We reported the short-term in vivo efficacy of subconjunctival bevacizumab for progressive corneal NV in a patient with LSC deficiency that underwent LSC transplantation. Four months after autologous LSC transplantation and 1 month after the second subconjunctival bevacizumab injection, the patient’s corrected distance visual acuity was 1/10.Conclusion: Subconjunctival injection of bevacizumab can reduce the corneal NV, reducing conjunctival inflammation and supporting restoration of a stable ocular surface that is able to counteract graft failure, with no toxicity for the transplanted LSC. Keywords: stem cells, bevacizumab, limbal stem cell deficiency, transplantation |
| format |
article |
| author |
Cavallini GM Pellegrini G Volante V Ducange P De Maria M Torlai G Benatti C Forlini M |
| author_facet |
Cavallini GM Pellegrini G Volante V Ducange P De Maria M Torlai G Benatti C Forlini M |
| author_sort |
Cavallini GM |
| title |
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| title_short |
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| title_full |
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| title_fullStr |
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| title_full_unstemmed |
Chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| title_sort |
chemical injury treated with autologous limbal epithelial stem cell transplantation and subconjunctival bevacizumab |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/9b2b493dad8b492d8f6537d9d4349205 |
| work_keys_str_mv |
AT cavallinigm chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT pellegrinig chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT volantev chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT ducangep chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT demariam chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT torlaig chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT benattic chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab AT forlinim chemicalinjurytreatedwithautologouslimbalepithelialstemcelltransplantationandnbspsubconjunctivalbevacizumab |
| _version_ |
1718402059488722944 |